Haoyu Wu

Haoyu Wu

Auto-generated profile, based on publicly available information

Haoyu Wu

Department of Epidemiology, Biostatistics, and Occupational Health McGill University Montreal Canada

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Circulation: Genomic and Precision Medicine
Verified
Journal Article
Closed access
PDF file
HWHaoyu Wu
Haoyu Wu
VFVincenzo Forgetta
Vincenzo Forgetta
SZSirui Zhou
Sirui Zhou
SBSahir Bhatnagar
Sahir Bhatnagar
GPGuillaume Paré
Guillaume Paré
JRJ. Brent Richards
J. Brent Richards
Background - The clinical implications of a polygenic risk score (PRS) for low-density lipoprotein cholesterol (LDL-C) are not well understood, both within the general population and individuals with familial hypercholesterolemia (FH). Methods - We developed the LDL-C PRS using LASSO regression in 377,286 white British participants from UK Biobank and tested its association with LDL-C according to FH variant carrier status in another 41,748 whole-exome sequenced individuals. Next, we tested for an enrichment of FH variant carriers amongst individuals with severe hypercholesterolemia and low LDL-C PRS. Last, we contrasted the effect of the LDL-C PRS, measured LDL-C and FH variant carrier status on risk of ischemic heart disease (IHD) amongst 3,010 cases and 38,738 controls. Results - Amongst the 41,748 whole-exome sequenced white British individuals, one SD increase in the LDL-C PRS was associated with elevated LDL-C amongst both FH variant carriers (0.34, 95% CI 0.22 to 0.47 mmol/L) and non-carriers (0.42, 95% CI 0.42 to 0.43 mmol/L). Amongst individuals with severe hypercholesterolemia, FH variant carriers were enriched in those with a low LDL-C PRS (OR 2.20, 95% CI 1.66 to 2.71 per SD). Each SD increase in the LDL-C PRS was associated with risk of IHD to the comparable magnitude as measured LDL-C (OR 1.24, 95% CI 1.20 to 1.29 and OR 1.15, 95% CI 1.09 to 1.23, respectively). The LDL-C PRS was not strongly associated with other traditional IHD risk factors. Conclusions - An LDL-C PRS could be used to identify individuals with a higher probability of harboring FH variants. The association between IHD and the LDL-C PRS was comparable to measured LDL-C, likely because the PRS reflects lifetime exposure to LDL-C levels.

1 October 2021 in Circulation: Genomic and Precision Medicine
Verified
Journal Article
Closed access
PDF file
HWHaoyu Wu
Haoyu Wu
JLJian’aN Luan
Jian’aN Luan
VFVincenzo Forgetta
Vincenzo Forgetta
JEJames C. Engert
James C. Engert
GTGeorge Thanassoulis
George Thanassoulis
JRJ. Brent Richards
J. Brent Richards
Background: Current lipid guidelines suggest measurement of Lp(a) (lipoprotein[a]) and ApoB (apolipoprotein B) for atherosclerotic cardiovascular disease risk assessment. Polygenic risk scores (PRSs) for Lp(a) and ApoB may identify individuals unlikely to have elevated Lp(a) or ApoB and thus reduce such suggested testing. Methods: PRSs were developed using least absolute shrinkage and selection operator regression among 273 222 and 356 958 UK Biobank participants of white British ancestry for Lp(a) and ApoB, respectively, and validated in separate sets of 60 771 UK Biobank and 15 050 European Prospective Investigation into Cancer and Nutrition-Norfolk participants. We then assessed the proportion of participants who, based on these PRSs, were unlikely to benefit from Lp(a) or ApoB measurements, according to current lipid guidelines. Results: In the UK Biobank and European Prospective Investigation into Cancer and Nutrition-Norfolk cohorts, the area under the receiver operating curve for the PRS-predicted Lp(a) and ApoB to identify individuals with elevated Lp(a) and ApoB was at least 0.91 (95% CI, 0.90–0.92) and 0.74 (95% CI, 0.73–0.75), respectively. The Lp(a) PRS and measured Lp(a) showed comparable association with atherosclerotic cardiovascular disease incidence, whereas the ApoB PRS was in general less predictive of atherosclerotic cardiovascular disease risk than measured ApoB. In the context of the European Society of Cardiology/European Atherosclerosis Society lipid guidelines, at a 95% sensitivity to identify individuals with elevated Lp(a) and ApoB levels, at least 54% of Lp(a) and 24% of ApoB testing could be reduced by prescreening with a PRS while maintaining a low false-negative rate. Conclusions: A substantial proportion of suggested testing for elevated Lp(a) and a modest proportion of testing for elevated ApoB could potentially be reduced by prescreening individuals with PRSs.

12 July 2024 in Canadian Journal of Statistics
Verified
Journal Article
Open access
HWHaoyu Wu
Haoyu Wu
DSDavid A. Stephens
David A. Stephens
EMErica E. M. Moodie
Erica E. M. Moodie
Estimating the COVID‐19 infection fatality rate, inferring the latent incidence and predicting the future epidemic evolution are critical to public health surveillance, but often challenging due to limited data availability or quality. Recently, a Bayesian framework combining time series deconvolution of deaths with a parametric Susceptible–Infectious–Recovered (SIR) model was proposed by Irons and Raftery, 2021. We assess the parameter identifiability of the model using the profile likelihood approach and simulations, when only the time series of deaths and seroprevalence survey data are available. The robustness of the model to the more complex but also more realistic Susceptible–Exposed–Infectious–Recovered (SEIR)‐based epidemics is evaluated through simulations; the influence of potential biases in the serosurveys on the inference is also investigated. We use a stationary first‐order autoregressive prior to account for the variability of transmission rate over time. The results suggest that the model is relatively robust to SEIR‐based epidemics, especially when the reproductive number is low, given sufficient information from serosurveys or priors. However, the lack of parameter identifiability under limited data availability cannot be neglected. We apply the model to infer the COVID‐19 infections in Ontario and Quebec, Canada during the Omicron era.

1 October 2021 in Journal of Investigative Medicine
Verified
Journal Article
Open access
PDF file
HWHaoyu Wu
Haoyu Wu
CWChen Wang
Chen Wang
GTGulinigaer Tuerhongjiang
Gulinigaer Tuerhongjiang
XQXiangrui Qiao
Xiangrui Qiao
YHYiming Hua
Yiming Hua
ZYZuyi Yuan
Zuyi Yuan
Recent studies showed that lipoproteins represent major risk factors, both positive and negative, for atherosclerotic cardiovascular disease. The aim of the present study was to describe the relationship between plasma lipid profile and cardiac function and cardiovascular outcomes in patients with acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI). Two independent groups of subjects including a total of 797 patients diagnosed of AMI undergoing PCI admitted to the First Affiliated Hospital of Xi'an Jiaotong University were included in the present study. We performed a cross-sectional study for the correlation between plasma lipid profile and cardiac function based on the first group, including 503 patients with AMI. We further validated the correlation and did the follow-up of 2.4 years of major cardiovascular outcomes on the second group, including 294 patients with AMI. Our results showed that apolipoprotein A-I (ApoA-I) level was significantly reduced, and the high-density lipoprotein cholesterol (HDL-C):ApoA-I ratio was increased in the patients with lower LVEF or higher N-terminal pro-B-type natriuretic peptide levels compared with the control; there was a positive correlation between cardiac function and ApoA-I, and a negative correlation between cardiac function and the HDL-C:ApoA-I ratio. Meanwhile, multivariate Cox analysis showed that ApoA-I was independent predictors of major adverse cardiovascular events (MACEs). Kaplan-Meier survival analysis showed the ApoA-I levels exhibited a significant effect on predicting the incidence of MACEs. In sum, plasma ApoA-I level is positively associated with the cardiac function of patients with AMI after PCI, and ApoA-I is an independent indicator to predict the incidence of MACEs.

7 October 2026 in Biometrics
Verified
Journal Article
Open access
HWHaoyu Wu
Haoyu Wu
DSDavid A Stephens
David A Stephens
EMErica E M Moodie
Erica E M Moodie
Statistical modeling of infectious disease outbreaks with incidence data is crucial to understanding epidemic dynamics and informing public health interventions. Stochastic epidemic models (SEMs) account for the inherent stochasticity in epidemic evolution and are particularly useful in small outbreaks or low-prevalence settings. In SEMs, the epidemic is naturally represented as a continuous-time Markov jump process (MJP), while surveillance data are collected at discrete times and subject to underdetection. Fitting SEMs to partially observed epidemic trajectories requires integrating over all possible transition paths, which is often intractable. Individual-level data augmentation (DA) methods have been developed to address these challenges. However, existing approaches either rely on per-subject updates with limited scalability or impose typically unrealistic assumptions to simplify the complex dimensional change problem for state-space SEMs. We present an efficient DA Markov chain Monte Carlo (MCMC) framework for fitting continuous-time state-space SEMs to incidence data. Our method uses a block sampler to jointly update individual trajectories and proposes transition times using a discrete-time approximation to the latent MJP. Through simulation studies, we demonstrate that our method significantly improves MCMC mixing and scalability compared to the previous DA approach and remains computationally robust in scenarios where particle MCMC algorithms struggle. We apply the method to the 2014 Ebola outbreak in a rural village in Sierra Leone and the 2009 H1N1 outbreak in a remote community in Canada.